UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure
Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.
Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."
AstraZeneca closed at $45.80 on Thursday.
Latest Ratings for AZN
|Feb 2015||SEB Equity Research||Upgrades||Hold||Buy|
|Jan 2015||Leerink Swann||Maintains||Market Perform|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.